APA (7th ed.) Citation

GL, R., KE, B., LM, K., PS, A., MW, B., & DE, M. (2011). Pre-Clinical Assessment of Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease. Pharmaceuticals (Basel, Switzerland), 5(1), 1. https://doi.org/10.3390/ph5010001

Chicago Style (17th ed.) Citation

GL, Ray, Baidoo KE, Keller LM, Albert PS, Brechbiel MW, and Milenic DE. "Pre-Clinical Assessment of Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease." Pharmaceuticals (Basel, Switzerland) 5, no. 1 (2011): 1. https://doi.org/10.3390/ph5010001.

MLA (9th ed.) Citation

GL, Ray, et al. "Pre-Clinical Assessment of Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease." Pharmaceuticals (Basel, Switzerland), vol. 5, no. 1, 2011, p. 1, https://doi.org/10.3390/ph5010001.